This combination therapy contains Rosuvastatin (a lipid-lowering statin), Aspirin (an antiplatelet agent), and Clopidogrel (a platelet aggregation inhibitor). It is primarily indicated for the prevention of cardiovascular events in patients at high risk of heart attack, stroke, and atherosclerotic disease. Rosuvastatin works by reducing LDL (bad cholesterol), total cholesterol, and triglycerides while increasing HDL (good cholesterol). Aspirin and Clopidogrel together prevent platelet aggregation, reducing the risk of clot formation inside blood vessels. This triple-combination therapy is commonly prescribed for patients with: Coronary artery disease (CAD) Acute coronary syndrome (ACS) Post-angioplasty or stent placement History of myocardial infarction Stroke prevention in high-risk individuals It provides comprehensive cardiovascular protection by targeting both cholesterol buildup and clot formation.
